Madam, I think the issue is not in our control. The drug companies decide which drugs have been proven to be effective in other jurisdictions. They bring them to Health Canada. Health Canada determines whether the drug is safe and effective and passes it on to other organizations, including CDR, and now JODR. So it's not a question of how many drugs we can handle. They come to us without our control. The issues here are the transparency, the expertise, the representation by the patients, the bases on which decisions are made. They're very narrowly defined bases, which have to change, and you have to take into account many more aspects of human living than just the cost of one year of life. I think we would all agree with that.
Some drugs, for example, are so powerful that they can make money for the economy if they're processed properly. They are so powerful and they cure patients so quickly that patients return to normal life, pay taxes, and contribute to the GDP. Those drugs, in fact, examples of which we've given in the past, have been stymied through this review process. So it's not a question of how many drugs we can handle. It's the process from CDR that we think is flawed, and those flaws will be translated into the new JODR. We have no confidence that they won't be, unless you intercede.